Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Profile Name | BRAF V600E BRAF over exp |
Gene Variant Detail | |
Relevant Treatment Approaches |
Molecular Profile | Indication/Tumor Type | Response Type | Relevant Treatment Approaches | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|---|
BRAF V600E BRAF over exp | melanoma | sensitive | PLX8394 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, PLX8394 treatment inhibited Erk signaling and reduced tumor growth in a Zelboraf (vemurafenib)-resistant cell line xenograft model of melanoma overexpressing BRAF V600E (PMID: 30559419). | 30559419 | |
BRAF V600E BRAF over exp | melanoma | resistant | Vemurafenib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, a cell line xenograft model of melanoma overexpressing BRAF V600E demonstrated resistance to Zelboraf (vemurafenib) treatment (PMID: 30559419). | 30559419 | |
BRAF V600E BRAF over exp | melanoma | resistant | Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line overexpressing BRAF V600E was resistant to Mekinist (trametinib) in culture (PMID: 36622773). | 36622773 | |
BRAF V600E BRAF over exp | melanoma | resistant | Dabrafenib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line overexpressing BRAF V600E was resistant to Tafinlar (dabrafenib) in culture (PMID: 36622773). | 36622773 | |
BRAF V600E BRAF over exp | melanoma | resistant | Dabrafenib + Trametinib | Preclinical - Cell culture | Actionable | In a preclinical study, a melanoma cell line overexpressing BRAF V600E was resistant to the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) in culture (PMID: 36622773). | 36622773 | |
BRAF V600E BRAF over exp | melanoma | predicted - sensitive | DS03090629 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, DS03090629 inhibited Erk but not Mek phosphorylation and proliferation in a melanoma cell line overexpressing BRAF V600E in culture and led to tumor stasis in a cell line xenograft model (PMID: 36622773). | 36622773 | |
BRAF V600E BRAF over exp | melanoma | sensitive | Dabrafenib + DS03090629 | Preclinical - Cell line xenograft | Actionable | In a preclinical study, the combination of DS03090629 and Tafinlar (dabrafenib) inhibited Erk phosphorylation and proliferation in a melanoma cell line overexpressing BRAF V600E in culture and induced tumor regression in a cell line xenograft model (PMID: 36622773). | 36622773 |